IRIS
BLANDINI, FABIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.344
AS - Asia 3.221
EU - Europa 2.705
SA - Sud America 499
AF - Africa 68
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 3
Totale 11.853
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.213
CN - Cina 1.394
IE - Irlanda 974
SG - Singapore 882
HK - Hong Kong 542
BR - Brasile 416
RU - Federazione Russa 388
DE - Germania 310
FI - Finlandia 250
UA - Ucraina 203
IT - Italia 152
VN - Vietnam 123
GB - Regno Unito 109
SE - Svezia 86
CA - Canada 84
JP - Giappone 53
FR - Francia 51
IN - India 47
CZ - Repubblica Ceca 37
AR - Argentina 33
MX - Messico 33
ZA - Sudafrica 27
IQ - Iraq 24
PL - Polonia 24
BE - Belgio 23
BD - Bangladesh 22
TR - Turchia 21
AT - Austria 20
ES - Italia 17
LT - Lituania 17
MU - Mauritius 14
PK - Pakistan 14
EC - Ecuador 13
ID - Indonesia 13
AU - Australia 11
NL - Olanda 10
PY - Paraguay 10
AZ - Azerbaigian 9
SA - Arabia Saudita 9
JO - Giordania 7
MA - Marocco 7
PE - Perù 7
CL - Cile 6
CO - Colombia 6
EG - Egitto 6
KZ - Kazakistan 6
KG - Kirghizistan 5
UY - Uruguay 5
AL - Albania 4
CH - Svizzera 4
DO - Repubblica Dominicana 4
KR - Corea 4
LB - Libano 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
AM - Armenia 3
BH - Bahrain 3
CY - Cipro 3
EU - Europa 3
GT - Guatemala 3
IL - Israele 3
IS - Islanda 3
LV - Lettonia 3
RO - Romania 3
BG - Bulgaria 2
BN - Brunei Darussalam 2
EE - Estonia 2
GE - Georgia 2
KE - Kenya 2
LK - Sri Lanka 2
LU - Lussemburgo 2
MR - Mauritania 2
MY - Malesia 2
NG - Nigeria 2
NP - Nepal 2
NZ - Nuova Zelanda 2
OM - Oman 2
PH - Filippine 2
RS - Serbia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TJ - Tagikistan 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CD - Congo 1
DK - Danimarca 1
DM - Dominica 1
GA - Gabon 1
GM - Gambi 1
GR - Grecia 1
GY - Guiana 1
HU - Ungheria 1
IR - Iran 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
LY - Libia 1
MD - Moldavia 1
Totale 11.843
Salva come PNG Salva come JPEG
Città #
Chandler 1.008
Dublin 974
Hong Kong 538
Dallas 502
Ashburn 485
Beijing 371
Singapore 368
Jacksonville 253
Boardman 228
Princeton 190
Lawrence 186
Nanjing 177
Medford 152
Wilmington 136
Los Angeles 127
Helsinki 115
New York 96
Munich 86
Shanghai 86
Redondo Beach 79
Nanchang 77
Buffalo 69
Shenyang 69
Changsha 61
Moscow 56
São Paulo 52
Tokyo 51
The Dalles 50
Toronto 50
Chicago 49
Ho Chi Minh City 49
Hebei 45
Tianjin 45
Ann Arbor 43
Jiaxing 42
Pavia 36
Brno 32
Hangzhou 31
Norwalk 31
Brooklyn 30
San Francisco 28
Hanoi 27
Milan 27
Santa Clara 27
Washington 26
Columbus 25
Turku 25
Brussels 23
Chennai 23
Warsaw 21
Falkenstein 20
Stockholm 20
Denver 19
Orem 19
Boston 18
Seattle 18
Johannesburg 17
London 17
Nuremberg 17
Guangzhou 16
Piscataway 16
Atlanta 15
Montreal 15
Phoenix 15
Düsseldorf 14
Fairfield 14
Woodbridge 14
Manchester 13
Rio de Janeiro 12
Belo Horizonte 11
Elk Grove Village 11
Philadelphia 11
Des Moines 10
Mexico City 10
Vienna 10
Baghdad 9
Baku 9
Poplar 9
Rome 9
Shijiazhuang 9
Wuhan 9
Zhengzhou 9
Ankara 8
Houston 8
Querétaro 8
Amman 7
Curitiba 7
Frankfurt am Main 7
Jinan 7
Mariglianella 7
New Delhi 7
Paris 7
Verona 7
Cairo 6
Kunming 6
Lahore 6
Newark 6
Ningbo 6
Xi'an 6
Bishkek 5
Totale 7.933
Salva come PNG Salva come JPEG
Nome #
Correlation of LTP and LTD with gene expression in the cerebellar cortex. 150
Alterazioni neurochimiche del sistema nervoso enterico (SNE) in un modello sperimentale di Parkinson 138
Intestinal dysmotility and enteric neurochemical changes in a Parkinson's disease rat model 133
Acute Reduction of Anandamide-Hydrolase (FAAH) Activity is Coupled With a Reduction of Nociceptive Pathways Facilitation in Medication-Overuse Headache Subjects After Withdrawal Treatment. 129
A new 5-HT2 antagonist (ritanserin) in the treatment of chronic headache with depression. A double-blind study vs amitriptyline. 123
Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms 119
Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. 119
Aging and dementia: markers of the hypothalamus-pituitary-adrenal axis and sympathetic activities in biological fluids 111
Immediate early genes regulation in rat cerebellar cortex during long-term synaptic plasticity induction. 111
Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells 111
Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 110
Activation of the CREB/c-Fos Pathway during Long-Term Synaptic Plasticity in the Cerebellum Granular Layer 108
Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats 106
Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: Relevance to gastrointestinal dysfunctions in Parkinson's disease 106
Immediate early genes expression in the cerebellar cortex correlates with LTP and LTD induction. 105
Stress and Autonomic Nervous System 98
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease 98
Long-term synaptic plasticity and related gene expression in the cerebellar cortex. 97
Endothelial nitric oxide synthase inhibition triggers inflammatory responses in the brain of male rats exposed to ischemia-reperfusion injury 96
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease 96
Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: Potential relevance to the pathophysiology of Parkinson's disease 94
Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson's disease: a self perpetuating crosstalk? 93
Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson's disease 93
Radiological analysis of gastrointestinal dysmotility in a model of central nervous dopaminergic degeneration: Comparative study with conventional in vivo techniques in the rat 88
An update on the use of non-ergot dopamine agonists for the treatment of Parkinson’s disease 88
Functional changes of the basal ganglia circuitry in Parkinson's disease. 85
Immediate early genes expression in the cerebellar cortex correlates with LTP and LTD induction. 85
Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: Potential targets for a new therapeutic approach 85
A 2A receptor antagonism and dyskinesia in parkinson's disease 85
In vivo imaging of early signs of dopaminergic neuronal death in an animal model of Parkinson's disease 84
Peripheral expression of key regulatory kinases in Alzheimer's disease and Parkinson's disease 84
Inefficient DNA Repair Is an Aging-Related Modifier of Parkinson's Disease 82
Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease. 81
Nitroglycerin-induced activation of monoaminergic trasmission in the rat 79
Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease 79
Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease 79
The role of dopamine in the modulation of gastrointestinal motility in a rat model of Parkinson's disease 78
A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease 78
A reliable indirect cell-labelling protocol for optical imaging allows ex vivo visualisation of mesenchymal stem cells after transplantation 78
Pro-oxidant activity and methionine metabolism in chronic alcohol abusers: relationship to alcohol withdrawal and folate administration 78
Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease 78
Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson's disease. 77
Gba mutations influence the release and pathological effects of small extracellular vesicles from fibroblasts of patients with parkinson’s disease 77
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 76
Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity 76
Dietary restriction does not prevent nigrostriatal degeneration in the 6-hydroxydopamine model of Parkinson's disease 76
Intracarotid infusion of mesenchymal stem cells in an animal model of Parkinson’s disease, focusing on cell distribution and neuroprotective and behavioral effects 75
Oxidative stress and pro-apoptotic conditions in a rodent model of Wilson's disease. 74
Complex Changes in the Innate and Adaptive Immunity Accompany Progressive Degeneration of the Nigrostriatal Pathway Induced by Intrastriatal Injection of 6-Hydroxydopamine in the Rat 74
Age-related changes of protein SUMOylation balance in the AβPP Tg2576 mouse model of Alzheimer's disease 74
Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson's disease 74
Repurposing opportunities for Parkinson’s disease therapies 74
Modulation of RAGE isoforms expression in the brain and plasma of rats exposed to transient focal cerebral ischemia. 73
Peripheral inflammation and neuroprotection: Systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease 73
Homocysteine and Parkinson's disease: a dangerous liaison? 72
Effects of the intrastriatal administration of selective dopaminergic agonists on Fos expression in the rat brain. 72
Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. 72
Valutazione delle catecolamine plasmatiche: influenza di fattori ambientali e delle procedure di campionamento 72
Parkinson's disease patients have a complex phenotypic and functional Th1 bias: Cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients 72
Mitochondrial Complex i Reversible S-Nitrosation Improves Bioenergetics and Is Protective in Parkinson's Disease 72
Cardiopressor effects of short-term treatment with cabergoline in L-Dopa stable responder parkinsonian patients: Relevance of postprandial hypotension 72
Proteasomal inhibition and apoptosis regulatory changes in human isolated lymphocytes: The synergistic role of dopamine 72
Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations 72
From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries 71
Intestinal dysmotility and enteric neurochemical changes in a Parkinson's disease rat model. 71
Fibroblasts from skin biopsies as a tool for biomarker discovery in Parkinson׳s disease 71
Dual target strategy: Combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l -DOPA-induced rotational behavior in a rodent model of Parkinson's disease 71
Noninvasive neuromodulation in Parkinson's disease: Neuroplasticity implication and therapeutic perspectives 71
Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine 70
Glucocerebrosidase Defects as a Major Risk Factor for Parkinson’s Disease 70
Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms 70
Long-term culture and differentiation of CNS precursors derived from anterior human neural rosettes following exposure to ventralizing factors 70
Naproxen Sodium in Menstrual Migraine Prophylaxis: A Double‐Blind Placebo Controlled Study 70
Electrophysiological and metabolic effects of CHF5074 in the hippocampus: Protection against in vitro ischemia 69
The Involvement of Post-Translational Modifications in Alzheimer's Disease 68
Activation of brain metabolism and fos during limbic seizures: The role of Locus Coeruleus 68
Modulation of noradrenergic activity by magnesium salts in panic disorder and neuronal hyperexcitability syndrome 67
Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease 67
Selective lesion of the substantia nigra pars reticulata reduces the cortical Fos expression induced by stimulation of striatal D1-like receptors, in the rat 67
Systemic administration of ephedrine induces Fos protein expression in caudate putamen and subthalamic nucleus of rats. 67
Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease 67
Free plasma catecholamine levels in healthy subjects: a basal and dynamic study 66
Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration 66
Gender biased neuroprotective effect of Transferrin Receptor 2 deletion in multiple models of Parkinson’s disease 66
Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease. 65
Intestinal dysmotility and enteric neurochemical changes following nigrostriatal dopaminergic denervation in the rat: relevance to the gastrointestinal dysfunction associated with Parkinson's disease 65
The exosomal/total α-synuclein ratio in plasma is associated with glucocerebrosidase activity and correlates with measures of disease severity in PD patients 65
Dopaminergic Modulation of Apoptosis in Human Peripheral Blood Mononuclear Cells: Possible Relevance for Parkinson's Disease 65
Rationale and design of the CV-PREVITAL study: an Italian multiple cohort randomised controlled trial investigating innovative digital strategies in primary cardiovascular prevention 64
Peripheral levels of BDNF and NGF in primary headaches 64
Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson's Disease 64
Animal models of Parkinson's disease 64
Movement disorders and aging. 62
Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia. 62
An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease 62
Facemasks and face recognition: Potential impact on synaptic plasticity 62
Unilateral lesion of the subthalamic nucleus enhances cortical fos expression associated with focally evoked seizures in the rat 61
Evaluation of ADMA-DDAH-NOS axis in specific brain areas following nitroglycerin administration: study in an animal model of migraine 61
Influence of estrogen modulation on glia activation in a murine model of parkinson's disease 61
Potential therapeutic effects of polyphenols in Parkinson's disease: In vivo and in vitro pre-clinical studies 61
Totale 8.090
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.565
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.565
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021382 0 0 0 0 0 47 4 69 123 77 53 9
2021/2022816 6 2 34 6 4 16 12 43 51 11 122 509
2022/20232.712 302 199 43 236 218 259 0 165 1.184 9 55 42
2023/2024969 121 146 44 56 92 250 35 56 7 27 57 78
2024/20252.833 121 215 66 80 88 152 145 176 645 142 376 627
2025/20263.020 448 400 648 635 733 156 0 0 0 0 0 0
Totale 12.058